CA2854805C - Method of predicting breast cancer prognosis - Google Patents

Method of predicting breast cancer prognosis Download PDF

Info

Publication number
CA2854805C
CA2854805C CA2854805A CA2854805A CA2854805C CA 2854805 C CA2854805 C CA 2854805C CA 2854805 A CA2854805 A CA 2854805A CA 2854805 A CA2854805 A CA 2854805A CA 2854805 C CA2854805 C CA 2854805C
Authority
CA
Canada
Prior art keywords
breast cancer
recurrence
likelihood
rna
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2854805A
Other languages
English (en)
French (fr)
Other versions
CA2854805A1 (en
Inventor
Joffre B. Baker
Dominick V. Sinicropi
Robert J. Pelham
Michael Crager
Francois Collin
James C. STEPHANS
Mei-lan LIU
John Morlan
Kunbin Qu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of CA2854805A1 publication Critical patent/CA2854805A1/en
Application granted granted Critical
Publication of CA2854805C publication Critical patent/CA2854805C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2854805A 2011-11-08 2012-11-02 Method of predicting breast cancer prognosis Active CA2854805C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161557238P 2011-11-08 2011-11-08
US61/557,238 2011-11-08
US201261597426P 2012-02-10 2012-02-10
US61/597,426 2012-02-10
PCT/US2012/063313 WO2013070521A1 (en) 2011-11-08 2012-11-02 Method of predicting breast cancer prognosis

Publications (2)

Publication Number Publication Date
CA2854805A1 CA2854805A1 (en) 2013-05-16
CA2854805C true CA2854805C (en) 2021-04-27

Family

ID=48290467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2854805A Active CA2854805C (en) 2011-11-08 2012-11-02 Method of predicting breast cancer prognosis

Country Status (9)

Country Link
US (4) US20140296085A1 (https=)
EP (1) EP2776830B1 (https=)
JP (2) JP6147755B2 (https=)
AU (1) AU2012336120B2 (https=)
CA (1) CA2854805C (https=)
IL (4) IL232445B (https=)
MX (1) MX357402B (https=)
SG (2) SG11201402042PA (https=)
WO (1) WO2013070521A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
EP2648762B1 (en) 2010-12-09 2018-02-21 Biotheranostics, Inc. Post-treatment breast cancer prognosis
EP2898090B1 (en) * 2012-09-18 2017-11-08 Qiagen GmbH Method and kit for preparing a target rna depleted sample
US10487362B2 (en) * 2013-01-09 2019-11-26 Health Research, Inc. Methods for diagnosing cancer based on small nucleolar RNA HBII-52
WO2014130444A1 (en) * 2013-02-19 2014-08-28 Genomic Health, Inc. Method of predicting breast cancer prognosis
ES2829912T3 (es) * 2013-09-11 2021-06-02 Bio Theranostics Inc Predecir la reaparición de cáncer de mama
EP3063689A4 (en) * 2013-10-29 2017-08-30 Genomic Health, Inc. Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk
CN105214077B (zh) * 2014-06-03 2019-02-05 浙江阿思科力生物科技有限公司 Usp33在肿瘤中的应用
WO2016094330A2 (en) * 2014-12-08 2016-06-16 20/20 Genesystems, Inc Methods and machine learning systems for predicting the liklihood or risk of having cancer
BR112017012087A2 (pt) * 2014-12-10 2018-01-16 Koninklijke Philips Nv métodos de identificação de genes codificantes e não codificantes coexpressados, e sistema
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1
EP3365000B1 (en) * 2015-10-23 2020-06-10 Novartis AG Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
US11530448B2 (en) 2015-11-13 2022-12-20 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
EP3202913B1 (en) * 2016-02-08 2019-01-30 King Faisal Specialist Hospital And Research Centre A set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival
US12006553B2 (en) * 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
EP3802816A4 (en) * 2018-06-08 2022-03-23 Glympse Bio, Inc. Activity sensor design
CN108893537B (zh) * 2018-07-19 2020-10-30 青岛泱深生物医药有限公司 C7orf70及其应用
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
SG11202106398WA (en) * 2018-11-04 2021-07-29 Pfs Genomics Inc Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN109859801B (zh) * 2019-02-14 2023-09-19 辽宁省肿瘤医院 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US20240218448A1 (en) * 2020-04-23 2024-07-04 Board Of Regents, The University Of Texas System Methods and compositions related to full-length excised intron rnas (flexi rnas)
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
RU2763839C1 (ru) * 2021-04-27 2022-01-11 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Петрова" Минздрава России) Способ многофакторного прогноза рака молочной железы
CN113667749A (zh) * 2021-08-03 2021-11-19 广东省人民医院 四个关键基因组合评估乳腺癌风险的诊断试剂盒
CN114480650A (zh) * 2022-02-08 2022-05-13 深圳市陆为生物技术有限公司 一种预测三阴乳腺癌临床预后复发风险的标志物及模型
CN114657242B (zh) * 2022-03-16 2022-11-11 广州医科大学附属第一医院 Gpr33基因在马尔尼菲篮状菌易感人群评估的应用
CN121137157B (zh) * 2025-11-17 2026-02-10 长春科技学院 一种评估上皮性卵巢癌复发风险的试剂的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992643C (en) * 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
US7526387B2 (en) * 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
WO2006037485A2 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
EP2061885A4 (en) * 2006-09-15 2011-03-09 Univ Mcgill STROMA-DERIVED PREDICTOR FOR BREAST CANCER
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
EP2036988A1 (en) * 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009071655A2 (en) * 2007-12-06 2009-06-11 Siemens Healthcare Diagnostics Inc. Methods for breast cancer prognosis
US20110020370A1 (en) * 2008-12-11 2011-01-27 Elias Georges Slc7a5 directed diagnostics and therapeutics for neoplastic disease
CN101851611A (zh) * 2009-04-01 2010-10-06 天津医科大学附属肿瘤医院 驱动蛋白样蛋白kif1b的转移相关功能和预测肿瘤患者预后的标志物用途及其应用方法
WO2010127399A1 (en) * 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
WO2011044513A1 (en) * 2009-10-08 2011-04-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
CA3043089A1 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
US20120245235A1 (en) * 2009-12-01 2012-09-27 Compenda Bioscience, Inc Classification of cancers
GB0922437D0 (en) * 2009-12-22 2010-02-03 Cancer Rec Tech Ltd Hypoxia tumour markers
WO2011107819A1 (en) * 2010-03-01 2011-09-09 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
ES2525382T3 (es) * 2010-03-31 2014-12-23 Sividon Diagnostics Gmbh Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino

Also Published As

Publication number Publication date
JP2014532428A (ja) 2014-12-08
JP6147755B2 (ja) 2017-06-14
AU2012336120A1 (en) 2014-05-29
JP2017055769A (ja) 2017-03-23
IL261708A (en) 2018-10-31
US20200263257A1 (en) 2020-08-20
CA2854805A1 (en) 2013-05-16
EP2776830B1 (en) 2018-05-09
IL232445B (en) 2018-10-31
US20140296085A1 (en) 2014-10-02
IL276488A (en) 2020-09-30
WO2013070521A1 (en) 2013-05-16
EP2776830A4 (en) 2015-07-15
US20190256923A1 (en) 2019-08-22
MX2014005547A (es) 2014-08-29
IL276488B (en) 2021-04-29
IL232445A0 (en) 2014-06-30
US20160222463A1 (en) 2016-08-04
HK1201329A1 (en) 2015-08-28
SG10202010758SA (en) 2020-11-27
AU2012336120B2 (en) 2017-10-26
MX357402B (es) 2018-07-09
IL265136B (en) 2020-08-31
SG11201402042PA (en) 2014-06-27
EP2776830A1 (en) 2014-09-17
NZ624700A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
CA2854805C (en) Method of predicting breast cancer prognosis
US20240110242A1 (en) Systems and methods of diagnosing idiopathic pulmonary fibrosis
Chien et al. Cell-type-specific effects of age and sex on human cortical neurons
EP3179393B1 (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
Wang et al. Gene networks and microRNAs implicated in aggressive prostate cancer
US10169530B2 (en) Gene fusions and alternatively spliced junctions associated with breast cancer
JP6039656B2 (ja) 癌再発の予後予測のための方法および装置
US20140256564A1 (en) Methods of using hur-associated biomarkers to facilitate the diagnosis of, monitoring the disease status of, and the progression of treatment of breast cancers
US9836577B2 (en) Methods and devices for assessing risk of female infertility
WO2012174256A2 (en) Dna methylation profiles in cancer
US20200105367A1 (en) Methods of Incorporation of Transcript Chromosomal Locus Information for Identification of Biomarkers of Disease Recurrence Risk
WO2014014518A1 (en) Methods for treating, preventing and predicting risk of developing breast cancer
EP3119909B1 (en) Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd)
Loid et al. Aging promotes accumulation of senescent and multiciliated cells in human endometrial epithelium
US20250043355A1 (en) Pan-cancer transcriptional signature
US20240115699A1 (en) Use of cancer cell expression of cadherin 12 and cadherin 18 to treat muscle invasive and metastatic bladder cancers
US20220112561A1 (en) Methods for nucleic acid sequencing
WO2013130465A2 (en) Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
Latowska-Łysiak et al. Transcriptome-wide analysis of circRNA and RBP profiles and their molecular and clinical relevance for GBM
WO2014130444A1 (en) Method of predicting breast cancer prognosis
HK1201329B (en) Method of predicting breast cancer prognosis
WO2025221816A1 (en) Method and system of using biomarkers for xenograft damage or rejection
HK40035898A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
HK1237068B (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
HK1237068A1 (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171023

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025